A Comprehensive HRIG Solution
HyperRAB (300 IU/mL) is the first and only high-potency human rabies immune globulin (HRIG) that enables the delivery of more of the total dose per mL at the wound site, no matter the wound size or patient weight.1-3
HyperRAB is the only HRIG that offers all of the following1
- 1/2 the volume of medication administered in a total dose, potentially resulting in fewer injections
- 2X the concentration of rabies antibodies per mL at the wound site, no matter the size
- 3 vial sizes, including 1 mL, 3 mL, and 5 mL
- 3-year shelf life
- Room temperature storage* (up to 6 months)
- Reliable supply
- Rabies education
- Patient assistance program
Provide immediate protection with HyperRAB
HyperRAB is an HRIG that provides rapid immune coverage, indicated for postexposure prophylaxis (PEP), along with rabies vaccine, for all persons suspected of exposure to rabies.1,5 Review CDC guidelines for PEP.
For unvaccinated persons, the combination of HyperRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of PEP. Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.1,6
Grifols is the only manufacturer that has complete end-to-end control over the entire process—collection, testing, fractionation, and supply—enabling a consistent and reliable supply of HyperRAB.
Find out more about the unique manufacturing process for HyperRAB.
Dosing and Administration
Dosing recommendations for HyperRAB
The recommended dose for HyperRAB is 20 IU/kg (0.0665 mL/kg) of actual body weight administered at the time of the first vaccine dose.1 HyperRAB can be given up to 7 days after the first dose of rabies vaccine.6
Dosing Calculator
Enter your patient's actual body weight to determine their HyperRAB dose.†
PATIENT WEIGHT
UNITS
DOSE NEEDED (IU)
DOSE NEEDED (mL)
NUMBER OF VIALS†
QTY
1-mL VIAL(s)
QTY
3-mL VIAL(s)
QTY
5-mL VIAL(s)
Administer HRIG and the vaccine correctly
The most common causes of postexposure prophylaxis (PEP) management failures are when the HRIG is not fully administered, it is not administered into the wound(s) and injected only IM, or injections are not administered to all bite wound(s).8,9‡
More than 1 million patients treated4
Watch a video to learn more about the
proper administration of HyperRAB.
Clinical Efficacy
In an open-label, single-arm study of 12 healthy volunteers, rabies virus antibody titers were assessed following a single 20 IU/kg IM injection of HyperRAB. This was measured by a rapid fluorescent focus inhibition test (RFFIT).1, 10
HyperRAB (rabies immune globulin [human]) 300 IU/mL produced a substantial increase in antirabies virus antibody concentrations during a 21-day period in which peak values were achieved.1,10
- Elevated antibody levels and the corresponding reciprocal titers persisted through day 21
- Elevation in rabies antibody level was prompt and resulted in detectable titers of neutralizing antibody present by 24 hours (mean 0.113 IU/mL and mean titer 10.3 on day 1)
- The reciprocal titer results from this study are comparable to an earlier open-label, single-center study of HyperRAB S/D in 8 subjects given a 20 IU/kg dose IM
In the clinical study, subjects underwent a screening period of up to 21 days, when safety assessments and laboratory tests were performed to ascertain eligibility. A single IM dose of HyperRAB was administered to eligible subjects on day 0, followed by repeated measurements of rabies virus antibody concentrations on days 1, 2, 4, 6, 8, 10, 14, 18, and 21.1,10
Safety and Manufacturing
Continuing to raise the bar for what's possible from HyperRAB.
Grifols has provided more than 45 years of consistent supply and product support.
HyperRAB offers1,4:
How the unique HyperRAB manufacturing process works
The capacity of the HyperRAB manufacturing process to remove and/or inactivate viruses has been demonstrated by laboratory spiking studies on a scaled-down process model using a wide range of viruses with diverse physicochemical properties. This process provides the final product with a high margin of safety from the potential risk of transmission of infectious viruses.
The caprylate/chromatography manufacturing process was also investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the variant Creutzfeldt-Jakob disease (vCJD) and Creutzfeldt-Jakob disease (CJD) agents. These studies provide reasonable assurance that low levels of vCJD/CJD agent infectivity, if present in the starting material, would be removed by the caprylate/chromatography manufacturing process.
HyperRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the vCJD agent, and, theoretically, the CJD agent.
Additional safeguards for all plasma donations
Grifols employs a comprehensive tracking system called PediGri® that ensures full traceability from every donation.
- Each plasma unit is coded and computer-traced from the start of the process until the units are transformed into a final product
-
Users can access the donation number and the viral screening conducted at the origin of the donation with the product lot number
- Specific information is also available, including the total number of plasma units, the total volume of plasma, the certificate of analysis showing the plasma origin viral screening, and biochemical characteristics of the final product
- Users can access the applicable product SPC/package insert for their country
For immediate, easy, and convenient access to all the information on the origin and quality of Grifols' plasma derivatives, visit www.pedigri.grifols.com.
Coding Information
